SELLAS LIFE SCIENCES GROUP I (SLS) Fundamental Analysis & Valuation

NASDAQ:SLS • US81642T2096

Current stock price

4.46 USD
-0.18 (-3.88%)
At close:
4.61 USD
+0.15 (+3.36%)
After Hours:

This SLS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. SLS Profitability Analysis

1.1 Basic Checks

  • In the past year SLS has reported negative net income.
  • In the past year SLS has reported a negative cash flow from operations.
  • In the past 5 years SLS always reported negative net income.
  • SLS had a negative operating cash flow in each of the past 5 years.
SLS Yearly Net Income VS EBIT VS OCF VS FCFSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • SLS has a Return On Assets of -34.29%. This is in the better half of the industry: SLS outperforms 60.47% of its industry peers.
  • SLS's Return On Equity of -37.90% is fine compared to the rest of the industry. SLS outperforms 68.41% of its industry peers.
Industry RankSector Rank
ROA -34.29%
ROE -37.9%
ROIC N/A
ROA(3y)-319.06%
ROA(5y)-214.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLS Yearly ROA, ROE, ROICSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLS Yearly Profit, Operating, Gross MarginsSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. SLS Health Analysis

2.1 Basic Checks

  • SLS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SLS has been increased compared to 5 years ago.
  • SLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SLS Yearly Shares OutstandingSLS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
SLS Yearly Total Debt VS Total AssetsSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

  • SLS has an Altman-Z score of 59.24. This indicates that SLS is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of SLS (59.24) is better than 96.32% of its industry peers.
  • SLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 59.24
ROIC/WACCN/A
WACCN/A
SLS Yearly LT Debt VS Equity VS FCFSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • SLS has a Current Ratio of 10.72. This indicates that SLS is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 10.72, SLS belongs to the best of the industry, outperforming 82.17% of the companies in the same industry.
  • SLS has a Quick Ratio of 10.72. This indicates that SLS is financially healthy and has no problem in meeting its short term obligations.
  • SLS's Quick ratio of 10.72 is amongst the best of the industry. SLS outperforms 82.17% of its industry peers.
Industry RankSector Rank
Current Ratio 10.72
Quick Ratio 10.72
SLS Yearly Current Assets VS Current LiabilitesSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. SLS Growth Analysis

3.1 Past

  • SLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.92%, which is quite impressive.
EPS 1Y (TTM)51.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • SLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 75.70% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.62%
EPS Next 2Y2.5%
EPS Next 3Y12.25%
EPS Next 5Y75.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLS Yearly Revenue VS EstimatesSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2020 2021 2022 2023 2026 2027 2028 2029 2030 2031 200M 400M 600M
SLS Yearly EPS VS EstimatesSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -2K -4K -6K -8K -10K

More info and screens

Find the best growth stocksShow best growing peers

0

4. SLS Valuation Analysis

4.1 Price/Earnings Ratio

  • SLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLS Price Earnings VS Forward Price EarningsSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLS Per share dataSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

  • SLS's earnings are expected to grow with 12.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.5%
EPS Next 3Y12.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SLS Dividend Analysis

5.1 Amount

  • SLS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SLS Fundamentals: All Metrics, Ratios and Statistics

SELLAS LIFE SCIENCES GROUP I

NASDAQ:SLS (4/24/2026, 8:08:40 PM)

After market: 4.61 +0.15 (+3.36%)

4.46

-0.18 (-3.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19
Earnings (Next)05-11
Inst Owners19.84%
Inst Owner Change3.05%
Ins Owners0.45%
Ins Owner Change24.82%
Market Cap800.93M
Revenue(TTM)N/A
Net Income(TTM)-26.86M
Analysts82.86
Price Target8.84 (98.21%)
Short Float %29.99%
Short Ratio7.99
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.91%
Min EPS beat(2)9.99%
Max EPS beat(2)23.84%
EPS beat(4)4
Avg EPS beat(4)20.91%
Min EPS beat(4)9.99%
Max EPS beat(4)33.99%
EPS beat(8)7
Avg EPS beat(8)15.72%
EPS beat(12)8
Avg EPS beat(12)-834.19%
EPS beat(16)9
Avg EPS beat(16)-638.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)26.83%
PT rev (3m)26.83%
EPS NQ rev (1m)22.58%
EPS NQ rev (3m)26.15%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 11.3
P/tB 11.61
EV/EBITDA N/A
EPS(TTM)-0.25
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.2
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0
BVpS0.39
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -34.29%
ROE -37.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-319.06%
ROA(5y)-214.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.72
Quick Ratio 10.72
Altman-Z 59.24
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y0.62%
EPS Next 2Y2.5%
EPS Next 3Y12.25%
EPS Next 5Y75.7%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y4.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.71%
OCF growth 3YN/A
OCF growth 5YN/A

SELLAS LIFE SCIENCES GROUP I / SLS Fundamental Analysis FAQ

What is the fundamental rating for SLS stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLS.


Can you provide the valuation status for SELLAS LIFE SCIENCES GROUP I?

ChartMill assigns a valuation rating of 0 / 10 to SELLAS LIFE SCIENCES GROUP I (SLS). This can be considered as Overvalued.


Can you provide the profitability details for SELLAS LIFE SCIENCES GROUP I?

SELLAS LIFE SCIENCES GROUP I (SLS) has a profitability rating of 1 / 10.


Is the dividend of SELLAS LIFE SCIENCES GROUP I sustainable?

The dividend rating of SELLAS LIFE SCIENCES GROUP I (SLS) is 0 / 10 and the dividend payout ratio is 0%.